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Abstract
Background: In 2000, the prevalence of diabetes among the 46 countries of the WHO African
Region was estimated at 7.02 million people. Evidence from North America, Europe, Asia, Latin
America and the Caribbean indicates that diabetes exerts a heavy health and economic burden on
society. Unfortunately, there is a dearth of such evidence in the WHO African Region. The
objective of this study was to estimate the economic burden associated with diabetes mellitus in
the countries in the African Region.
Methods: Drawing information from various secondary sources, this study used standard cost-of-
illness methods to estimate: (a) the direct costs, i.e. those borne by the health systems and the
families in directly addressing the problem; and (b) the indirect costs, i.e. the losses in productivity
attributable to premature mortality, permanent disability and temporary disability caused by the
disease. Prevalence estimates of diabetes for the year 2000 were used to calculate direct and
indirect costs of diabetes mellitus. A discount rate of 3% was used to convert future earnings lost
into their present values. The economic burden analysis was done for three groups of countries,
i.e. 6 countries whose gross national income (GNI) per capita was greater than 8000 international
dollars (i.e. in purchasing power parity), 6 countries with Int$2000–7999 and 33 countries with less
than Int$2000. GNI for Zimbabwe was missing.
Results: The 7.02 million cases of diabetes recorded by countries of the African Region in 2000
resulted in a total economic loss of Int$25.51 billion (PPP). Approximately 43.65%, 10.03% and
46.32% of that loss was incurred by groups 1, 2 and 3 countries, respectively. This translated into
grand total economic loss of Int$11,431.6, Int$4,770.6 and Int$ 2,144.3 per diabetes case per year
in the three groups respectively.
Conclusion: In spite of data limitations, the estimates reported here show that diabetes imposes
a substantial economic burden on countries of the WHO African Region. That heavy burden
underscores the urgent need for increased investments in the prevention and management of
diabetes.
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Background
Diabetes mellitus is a disorder caused by insufficient or
absent production of the hormone 'insulin' by the pan-
creas [1]. WHO estimates that more than 180 million peo-
ple worldwide have diabetes [2]. An estimated 2.9 million
people died from diabetes, i.e. a case-fatality rate (CFR) of
0.0161 [3]. In 2000, the prevalence of diabetes in the
WHO African Region was estimated at 7.02 million peo-
ple, out of which about 0.702 million (10%) people had
type 1 diabetes and 6.318 million (90%) had type 2 dia-
betes [2]. About 113,100 people died from diabetes-
related causes, 561,600 were permanently disabled, and
6,458,400 experienced temporary disablement.
Diabetes exerts a heavy economic burden on society. This
burden is related to health system costs incurred by soci-
ety in managing the disease, indirect costs resulting from
productivity losses due to patient disability and prema-
ture mortality, time spent by family members accompany-
ing patients when seeking care, and intangible costs
(psychological pain to the family and loved ones).
Barcelo et al. [4] estimated the total annual cost associated
with diabetes in Latin America and the Caribbean as
US$65.216 billion (direct cost US$10.721 billion and
indirect cost US$54.495 billion). Shobhana et al. [5] esti-
mated that "with a conservative prevalence of 200,000
Type 1 diabetic subjects in India, the cost of treatment
could be as high as US$50 million...". The American Dia-
betes Association [6] estimated that the combined direct
and indirect costs of diabetes in 1997 were US$98 billion
in the United States of America. Hart, Espinosa and Rovira
[7] estimated the total direct costs of diabetes to be over
US$650 million in Spain where there were over 1.4 mil-
lion known diabetics in 1994. Gray and Fenn [8] esti-
mated the cost of type 1 diabetes in England and Wales to
be US$1.92 million or US$2042 per person. Unfortu-
nately, there is a dearth of similar evidence for the WHO
African Region.
This article focuses on the economic burden of diabetes in
the WHO African Region. It attempts to answer the ques-
tion: from societal perspective (specifically the ministries
of health and the families), what is the total cost of diabe-
tes to the Region? The specific objectives were to estimate:
(a) the direct costs, i.e. those borne by the health systems
and the families in directly addressing the problem; and
(b) the indirect costs, i.e. the losses in productivity attrib-
utable to premature mortality, permanent disability and
temporary disability associated with diabetes.
Methods
Overview of health systems in the WHO African region
One of the major threats to economic development con-
fronting the 46 Member States of the WHO African
Region is the growing burden of diabetes and other non-
communicable diseases. The effectiveness of prevention
and control of those diseases hinges largely on the health
system performance of its functions of leadership and
governance; health workforce; medical products, vaccines
and technologies; information; financing; and services
delivery.
In the Region, the total number of physicians are
2,281,643; nurses are 3,383,925; midwives are 111,895;
dentists are 506,898; pharmacists are 518,378; public and
environmental health workers are 177,887; community
health workers are 163,285; laboratory technicians are
274,011; other health workers are 1,361,467; and health
management and support workers are 2,521,510 [9].
The physician density per 1000 was 0.03–0.78 in 18 coun-
tries; 1.01–2.00 in 14 countries; 2.14–3.00 in 4 countries;
3.01–4.00 in 7 countries; and over 4.00 in 3 countries.
The nurse density per 1000 was 0.14–0.96 in 17 countries;
1.05–2.00 in 4 countries; 2.10–3.00 in 4 countries; 3.01–
4.00 in 8 countries; and over 4.00 in 13 countries. Labo-
ratory technician density varied from minimum of 0.01
per 1000 in Niger to a maximum of 0.65 per 1000 in Cote
D'Ivoire [9]. Sixty three percent of the 57 countries experi-
encing extreme shortages of health workers around the
world are in the African Region [10].
About 50% of the population in the Region lack access to
essential medicines [10]. The number of hospital beds per
100000 persons among 33 countries that had data was as
follows: 8 (24%) countries had 3–20 beds; 13 (39%)
countries had 21–40 beds; and 12 (36%) countries had
more than 40 beds per 100000 [9].
In 2005, the per capita total expenditure on health in pur-
chasing power parity international dollars (PPP Int$) was
$30 and less in 6 countries; $31–60 in 14 countries; $61–
90 in 8 countries; $91–120 in 4 countries; and $122–811
in 14 countries. General government expenditure on
health as a percentage of total expenditure on health was
30% and less in 7 countries; 31–50% in 13 countries; 51–
70% in 17 countries; and 71–90% in 9 countries [11].
The health systems challenges alluded to above have in
tandem led to the current situation where 47% of the pop-
ulation in the Region have no access to quality health
services [10]. Those health systems bottlenecks also ham-
per effective response to the growing burden of diabetes
and other non-communicable diseases.
Data
The study used the prevalence estimates of diabetes melli-
tus for 2000 from a WHO website [2]. The distribution by
age from Murray and Lopez [12] was used to disaggregateBMC International Health and Human Rights 2009, 9:6 http://www.biomedcentral.com/1472-698X/9/6
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the total number of people with diabetes into age groups.
The gross national income (GNI) per capita in purchasing
power parity (PPP) was obtained from a World Bank web-
site [13]. The implied PPP conversion rates used in con-
verting national currencies into current international
dollars were from an International Monetary Fund web-
site [14]. The prices of diabetes medicines were obtained
from a WHO/AFRO publication [15] and the "hotel"
component of hospital costs (i.e. excluding medicines and
diagnostic tests) were obtained from a WHO website [16].
The 46 member states in the WHO African Region were
classified into three groups using gross national income
(GNI) per capita expressed in purchasing power parity for
2005 (Table 1) [13].
Following Barcelo et al. [4], the direct costs related to treat-
ment of diabetes patients were obtained from one or more
countries in each group from various sources. Each
group's average cost figure for various health system
inputs and GNI was obtained and used in the analysis.
The different countries costs of different inputs used in
treatment of diabetes were converted into current interna-
tional dollar equivalents using PPP conversion rates to
ensure that costs for different inputs were similar in each
country group. For example, the Mauritian Lipid test cost
of Int$28.9 was obtained by dividing the local cost for
Lipid profile test R424 by the implied PPP conversion rate
of 14.677. A discount rate of 3% was used to convert
future indirect cost flows into their present values [4].
Conceptual framework
Figure 1 presents a conceptual framework of the economic
burden of diabetes. The figure indicates the three alterna-
tive approaches for estimating the economic burden of a
public health problem like diabetes. These include: the
willingness-to-pay approach [17], the macroeconomic/
production function approach [18], and the cost-of-ill-
ness [19] approach. This study employed the last
approach.
Definition of costs estimated
The economic burden of diabetes comprises of direct
costs, indirect costs and intangible costs. Direct costs has
two components. First, the costs of organizing and operat-
ing hospital services: hotel costs (human resources-for-
health time, utilities, food, non-pharmaceutical supplies,
diagnostic equipment, building space), diagnostic tests
(HBA1c test, lipid profile, proteinuria test, blood sugar
test, electrocardiogram), medicines (insulin, oral drugs)
and devices for injecting insulin (syringes). Second, the
out-of-pocket expenses borne by the patients and their
families, including health service provider consultation
fees, medicines, tests and transport.
The indirect costs consist of opportunity cost of time lost
due to morbidity (temporary disability and permanent
disability) and premature mortality. The morbidity-
related component includes the productivity losses of
time invested by patients in outpatient department con-
sultations, travel to and from hospitals, waiting for admis-
sion, and during institutionalized treatment; by relatives
accompanying patients during pre-admission consulta-
tions, travel to and from hospitals accompanying patients,
waiting for patients to be admitted, and visiting patients
after admission. The premature mortality-related cost
component is equal to the lost work-years due to prema-
ture death (i.e. retirement age minus age at death) times
average remuneration per year.
Table 1: Classification of countries according to gross national income per capita, PPP (at 2005 international dollars) in 2005
Group GNI per capita (International Dollars, PPP) Group GNI per capita
(International Dollars, PPP)
Countries
1. ≥ 8000 11,113 
(standard deviation = 1,950; Median = 
10,905)
Botswana, Equatorial Guinea, Gabon, 
Mauritius, Seychelles, South Africa
2. 2000–7999 3,995 
(standard deviation = 1,664; median = 
3,865)
Algeria, Angola, Cape Verde, Congo, 
Namibia, Swaziland
3. <2000 972 
(standard deviation = 437; median = 1020)
Benin, Burkina Faso, Burundi, Cameroon, 
Central African Republic, Chad, Comoros, 
Democratic Republic of Congo, Cote 
d'Ivoire, Eritrea, Ethiopia, Gambia, Ghana, 
Guinea, Guinea-Bissau, Kenya, Lesotho, 
Liberia, Madagascar, Malawi, Mali, Mauritania, 
Mozambique, Niger, Nigeria, Rwanda, Sao 
Tome and Principe, Senegal, Sierra Leone, 
Tanzania, Togo, Uganda, Zambia, Zimbabwe
Source: World Bank [10].
* GNI data on Zimbabwe was missing.BMC International Health and Human Rights 2009, 9:6 http://www.biomedcentral.com/1472-698X/9/6
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Intangible costs refer to welfare losses due to the physical
and psychological pain. Due to the stigma attached to
chronic diseases, the related psychic and social costs to the
affected families can be profound. Resource constraints
prohibited the collection of willingness-to-pay data that
would have facilitated the estimation of intangible costs.
Analytical model
The total cost (TC) incurred by ministries of health, diabe-
tes patients and family members can be expressed as fol-
lows:
TC = DC + IC + ITC
where: DC is direct cost, IC is indirect cost (which is value
of productivity time lost) and ITC is intangible cost
(including physical and psychological pain).
Direct costs
The total direct costs (DC) was estimated using following
equations:
Conceptual framework of the economic burden of diabetes Figure 1
Conceptual framework of the economic burden of diabetes.
Economic burden of diabetes 
Measurement approaches 
Intangible cost: 
i Physical  pain 
i Psychological  pain 
Cost-of-illness 
approach (debility, 
morbidity & mortality)
Macroeconomic / 
Production 
function approach
Direct cost  Indirect cost 
Short-term cost: 
Value of productive time 
lost due to diabetes 
Indirect cost: 
i Premature  mortality 
i Permanent  disability 
i Temporary  disability 
i  Time of family 
caregivers 
Household: 
i Prevention 
costs, e.g. 
exercise, diet 
i Treatment 
costs, e.g. 
transport, 
user fees 
i Other  health 
care access 
costs (e.g. 
bribes) 
Organization & 
operation of health 
system: 
i Prevention,  e.g. 
health education 
i Medicines  (insulin, 
oral drugs) 
i  Hotel costs (HRH 
time, utilities,  food, 
materials, equipment, 
building space)  
i Diagnostic  costs 
(HBA1c test, lipid 
profile, proteinuria 
test,  blood sugar, 
test, 
electrocardiogram) 
i Other  costs 
Willingness-to-pay 
approach BMC International Health and Human Rights 2009, 9:6 http://www.biomedcentral.com/1472-698X/9/6
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DC = TCI + TCS + TCR + TCM + TCD + TCOC + TCH + 
TCT + OoPE
where: TCI is total annual cost of insulin; TCS is total
annual cost of syringes; TCR is total annual cost of reagent
strips; TCM is total annual cost of glucose meters; TCD is
total cost of oral drugs; TCOC is total cost of OPD consul-
tations; TCH is total cost of hospitalization; TCT is total
cost of diabetes related test for all people with diabetes;
and OoPE is the out-of-pocket expenses borne by patients,
family members and relatives.
Insulin
The total annual cost of insulin for nth group of countries
(TCIn) was estimated using the following formula: TCIn =
(NIIn × AQP × Pin); where: NIIn is the total number of
patients in need of insulin, which is equal to all the Type
1 diabetes patients plus 5% of the Type 2 diabetes
patients; AQP is annual quantity of insulin consumed per
patient per year, i.e. 10000 IU [4]; Pin is the average price
per unit of insulin expressed in international dollars for
nth group of countries.
Syringes
The annual cost of syringes for nth group of countries
(TCSn) was obtained as follows:
TCSn = NIIn × DIY × Psn; where: DIY is the number of days
in a year and Psn is the average price per unit of syringe
expressed in international dollars for nth group of coun-
tries.
Reagent strips
The annual cost of reagent strips for nth group of countries
(TCRn) was obtained as follows:
TCSn = NIIn × TRSU  × DIY  × PRSn; where: TRSU is the
number of times a reagent strip is used in a day, DIY is the
number of days in a year and PRSn is the average price per
unit of reagent strip expressed in international dollars for
nth group of countries.
Glucose meters
The annual cost of glucose meters for nth group of coun-
tries (TCMn) was derived as follows: TCMn = [(ACn ×
QGMn)/A(0.03,5)]; where: QGMn is the quantity of glu-
cose meters needed, i.e. equal to the number of insulin
users; ACn is the annual equivalent cost of one glucose
meter in international dollars for nth group of countries;
and A(5,0.03) is the annuity factor calculated assuming a
5 year useful life and a 3% discount rate. The annuity fac-
tor was obtained using following formula:
 For example,
dividing the Group 1 countries average replacement cost
of Int$30.97 per glucose meter by the annuity factor yields
annual equivalent cost of 30.97/4.579707 =
Int$6.762441.
Oral drugs
The annual total cost of oral drugs for nth group of coun-
tries (TCDn) was calculated as follows: TCDn = NODn ×
NTY × PMn; NODn is the total number of people in need of
oral drugs in nth group of countries; NTY is the number of
500 mg Metformin tablets taken per person per year; and
PMn is the average PPP price per 500 mg Metformin tablet
in nth group of countries. In our estimation of the TCD, we
assumed that 80% of the total population with Type 2 dia-
betes in each group of countries will need oral drugs and
the total number of Metformin tablets needed per person
per year would be 1500 [4].
Outpatient consultations and hospitalizations
The hospital cost per hospital stay and per outpatient visit
represent only the "hotel" component, i.e. excluding
drugs and diagnostic tests and including other costs such
as personnel, capital and food costs. The "hotel" compo-
nent of the hospital costs were obtained from a WHO
website [16]. The cost of hospital outpatient department
consultations (TCOCn) was obtained as follows: TCOCn =
NDn × NV × CVn ; where: NDn is the total number of dia-
betics in nth group of countries; NV is the total number of
OPD visits by a diabetes patient per year in nth group of
countries; and CVn is the cost per OPD visit in interna-
tional dollars in nth group of countries. For example, the
TCOC for group 1 countries (NB = 974000, NV = 4, CVn =
Int$39.95) was 974000 × 4 × 39.9483333333333 =
Int$155638707.
The total cost of diabetes patient hospitalizations per year
in nth group of countries (CHOPn) was obtained as fol-
lows: CHOPn = NHPn × ALSn × CPIDn; where: NHP is the
total number of patients hospitalized (Type 1 + 5% of
Type 2), ALS is the average length of stay and CPID is the
cost per inpatient day. We assumed that all people with
diabetes will make four visits in a year to a hospital outpa-
tient department [5]. In addition, we assumed that all
patients with Type 1 diabetes plus 5% of patients with
Type 2 diabetes would require one hospitalization per
year [4] and that the average length of stay for diabetes
patients is 9 days. For example, the TCOC for group 1
countries (NHP = 146100, ALS = 9.08 CPID = Int$91.10)
was 146100 × 9.07979554747842 × 91.1008333333333
= Int$120850551.
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Tests
The total cost of diabetes related tests [4] for nth group of
countries (TCTn) was estimated as follows:
TCTn = (NDn) × (CHBAn + CLPn + CECGn + CPTn + CBSn);
where: NDn is the total number of people with diabetes;
CHBAn is the cost of one HBA1c test; CLPn is the cost of
one lipid profile; CECGn is the cost of one electrocardio-
gram; CPTn is the cost of one proteinuria test; and CBSn is
the cost of one blood sugar test. We estimated that, in a
year, a total of all the 7.02 million people with diabetes
would require one HBA1c test, one lipid profile test, one
proteinuria  test and one electrocardiogram. The average
cost of these tests for group 1 countries was obtained by
WHO Country Offices health systems staff from Mauri-
tius; group 2 from Congo, Namibia and Swaziland; and
group 3 from Kenya, Mauritania and Senegal. Let us illus-
trate calculations of TCT using group 1 data: ND =
974000; CHBA = Int$24.77368051; CLP =
Int$28.90262726; CECG = Int$16.515787; CPT =
Int$8.257893502; and CBS = Int$6.193420127. There-
fore,
TCT1 = (974000) × (24.77 + 28.9 +16.52 + 8.26 + 6.19) = 
Int$82,442,680.
Household out-of-pocket expenditures
The out-of-pocket expenses borne by patients, family
members and relatives in nth group of countries (OOPEn)
was obtained using the following formula: OOPEn = (NDn
× APPn); where: NDn is the total number of people with
diabetes; and APPn is the total annual spending of persons
with diabetes on health care provider consultation fees,
medicines, tests, transport and other inputs. For example,
in group 1 countries (ND1  = 974000, APP1 =
Int$45.7406284019997) OOPE was equal to OOPE =
974000 × 45.7406284019997 = Int$44,551,372.
The average household out-of-pocket expenditures were
obtained from the World Health Survey data [20] on Mau-
ritius for group 1; Congo, Namibia and Swaziland for
group 2; and Burkina Faso, Chad, Cote D'Ivoire,
Comoros, Ethiopia, Ghana, Kenya, Mali, Mauritania,
Malawi, Senegal, Zambia and Zimbabwe for group 3. The
household monthly health care expenditures was divided
by average household size of 6 members [20] to obtain
expenditure per person and then multiplied by 12 to
obtain the annual expenditure per person. The result was
then divided by the respective country's PPP conversion
rate [14] for 2005 to obtain the international dollar equiv-
alent.
Indirect costs
The total indirect costs (IC) of nth group of countries were
obtained using the following algorithm: ICn = (CTDn +
CPDn + CPMn + CPVn); where: CTDn is the total cost of pro-
ductive time lost due to diabetes-related temporary disa-
bility; CPDn is the total cost of productive time lost due to
permanent disability; CPMn is the total cost of productive
time lost due to diabetes-related premature mortality; and
CPVn is the productivity loss due to the work time lost by
relatives accompanying and visiting patients.
Cost of premature diabetes-related mortality (CPM)
A total of 15692, 8636 and 88772 people died from dia-
betes associated causes in group 1, group 2 and group 3
countries respectively [12]. The distribution of those
deaths across the five age brackets was obtained by multi-
plying the total number of diabetes deaths by the diabe-
tes-related probabilities of death from Murray and Lopez
[12]. Those authors provide the average age of onset and
the average duration of life lived with diabetes for age
brackets 0–4, 5–14, 15–44, 45–59 and 60+ years. The pro-
ductive life years lost (PLYL) for 15–44, 45–59 and 60+
years age brackets were obtained by subtracting the sum of
the average age of onset and average duration of life lived
with diabetes from the maximum life expectancy in the
African Region. The future PLYL for 0–4 and 5–14 years
age brackets were obtained by subtracting the sum of the
average age of onset, average duration of life lived with
diabetes and 14 years from the maximum life expectancy
in the African Region, respectively.
Total cost of premature diabetes-related mortality (CPM)
is sum of the cost of premature diabetes-related mortality
among persons aged 4 years and less, aged 5–14 years,
aged 15–44 years, aged 45–59 years, and aged 60 years
and above. The cost of premature diabetes-related mortal-
ity among persons of specific age group is the product of
number of deaths, total number of productive discounted
life years lost (i.e. years above 14 years of age) and gross
national income per capita per year (Int$).
In symbolic terms, CPM for ith age bracket can simply be
expressed as:  ; 
is the number of diabetes associated deaths within ith age
bracket for nth  group of countries; DPYLi  is the total
number of discounted productive life years lost among
persons of ith age bracket; and GNIPCn is the annual gross
national income per capita in PPP. The productive life
years lost were discounted at a rate of 3% [4].
Cost of diabetes-related permanent disability (CPD)
The total cost of productive time lost due to permanent
disability (CPDn) is the sum of cost of productive time lost
due to permanent disability among persons aged 15–44
CPM NDD DPYL GNIPC n
i
n
ii
n =× × NDDn
iBMC International Health and Human Rights 2009, 9:6 http://www.biomedcentral.com/1472-698X/9/6
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years, 45–59 years, and 60 years and over. The non-fatal
illness time lost among patients under 4 years and those
aged 5–14 years were not costed.
The cost of productive time lost due to permanent disabil-
ity among persons of various age groups was obtained by
multiplying the total number of permanently disabled
diabetics ( ), discounted average duration lived
with diabetes (DAD) per person, and gross national
income per capita per year (GNIPC). In symbolic terms,
CPD for ith age bracket in nth group of countries can sim-
ply be expressed as:  .
Total cost of productive time lost due to diabetes-related temporary 
disability (CTD)
Total productive time lost due to diabetes-related tempo-
rary disability (CTD) is the sum of cost of productive time
lost due to diabetes among persons aged 15–44 years, 45–
59 years, and 60 years and over. The non-fatal illness time
lost among patients aged 4 years and less and 5–14 years
was not costed.
The cost of productive time lost due to diabetes-related
temporary disability among persons of various age groups
was obtained by multiplying the total number with tem-
porary disability due to diabetes ( ), days of disabil-
ity (DD) and daily gross national income per capita
(DGNIPCn). Symbolically,   for ith age bracket in nth
group of countries can simply be expressed as:
.
Cost of productive time lost by caregivers (CPV)
The cost of the work time lost by accompanying/visiting
relatives is a product of the number of diabetes cases
(ND), number of persons travelling to a health facility
(i.e. the accompanying/visiting relatives) (VR), number of
days spent visiting a health facility per person per year
(NV) and daily gross national income per capita per day
(DGNIPC). Symbolically, CPV for ith age bracket in nth
group of countries can simply be expressed as:
.
The assumptions used in estimating direct and indirect
costs can be found in the 'Additional file 1: Data and
assumptions used in estimating indirect and direct costs
of diabetes in the WHO African Region'. All the cost esti-
mates reported in this paper are in 2005 international dol-
lars, i.e. purchasing power parity.
Results
Group 1 countries total costs
Table 2 presents estimates of direct and indirect costs of
diabetes in the WHO African Region in 2005 for groups 1,
2 and 3. In group 1 the total number of people with type
1 and type 2 diabetes were estimated at 97400 (10% of
total) and 876,600 (90% of total), respectively. The total
number of deaths among people with diabetes was esti-
mated at 15,692 (13.9% of total) (see 'additional file 1:
Data and assumptions used in estimating indirect and
direct costs of diabetes in the WHO African Region').
In group 1 the total economic loss attributable to diabetes
was Int$11,134,366,440. This estimate consisted of a total
direct cost of Int$853,220,791 (7.66%). Out of that direct
cost, 35.35% consisted of cost of insulin; 6.45% consisted
of cost of syringes; 9.29% consisted of cost of reagent
strips; 0.12% consisted of cost of glucose meters; 1.50%
consisted of cost of oral drugs; 18.24% consisted of cost of
outpatient consultations; 14.16% consisted of cost of hos-
pitalization; 9.66% consisted of cost of diabetes-related
diagnostic tests; and 5.22% for health care costs borne by
households (patients and their family members) in search
of diabetes treatment.
The indirect costs amounted to Int$10,281,145,649
(92.34% of total loss) worth of productive time that was
lost by people of the group 1 countries due to diabetes dis-
ease. Out of the total indirect cost, about 88.08% was
attributed to permanent disability; 1.06% to temporary
disability; 9.71% to premature diabetes associated mor-
tality; and 1.15% to productive time lost by family care
givers.
Group 2 countries total costs
In group 2 the total number of people with type 1 and
type 2 diabetes were estimated at 53600 and 482400,
respectively. The total number of deaths among people
with diabetes was estimated at 8636 (7.64% of grand
total) (see 'additional file 1: Data and assumptions used
in estimating indirect and direct costs of diabetes in the
WHO African Region').
The group 2 countries sustained a total economic loss
associated with diabetes of Int$2,557,038,027. It con-
sisted of a total direct cost of Int$523,183,964 (20.46%).
Out of that direct cost, 41.37% consisted of cost of insu-
lin; 4.15% consisted of cost of syringes; 5.98% consisted
of cost of reagent strips; 0.07% consisted of cost of glucose
meters; 2.42% consisted of cost of oral drugs; 15.06%
consisted of cost of outpatient consultations; 14.45% con-
sisted of cost of hospitalization; 9.23% consisted of cost
of diabetes-related diagnostic tests; and 7.26% were
health care costs borne by households (patients and their
family members) in search of diabetes treatment.
NPDn
i
CPD NPD DAD DGNIPC n
i
n
ii
n =××
NTDn
i
CTDn
i
CTD NTD DD GNIPC n
i
n
ii
n =× ×
CPV ND VR NV GNIPC n
i
n
i
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The indirect costs for group 2 countries amounted to
Int$2,033,854,063 (79.54% of total loss) worth of pro-
ductive time. Out of the total indirect cost, about 88.08%
was attributed to permanent disability; 1.06% to tempo-
rary disability; 9.71% to premature diabetes associated
mortality; and 1.15% to productive time lost by family
care givers.
Group 3 countries total costs
In group 3 the total number of people with type 1 and
type 2 diabetes were estimated at 551000 and 4959000,
respectively. The total number of deaths among people
with diabetes was estimated at 88772 (78.5% of grand
total) (see 'Additional file 1: Data and assumptions used
in estimating indirect and direct costs of diabetes in the
WHO African Region').
The group 3 countries sustained a total economic loss
associated with diabetes of Int$ 11,814,852,255. It con-
sisted of a total direct cost of Int$6,725,698,289
(56.93%). Out of that direct cost, 56.31% consisted of
cost of insulin; 5.65% consisted of cost of syringes; 8.14%
consisted of cost of reagent strips; 0.10% consisted of cost
of glucose meters; 3.61% consisted of cost of oral drugs;
1.64% consisted of cost of outpatient consultations;
1.90% consisted of cost of hospitalization; 15.41% con-
sisted of cost of diabetes-related diagnostic tests; and
7.24% were health care costs borne by households
(patients and their family members) in search of diabetes
treatment.
The indirect costs incurred by group 3 countries
amounted to Int$5,089,153,966 (43.07% of total loss)
worth of productive time. Out of the total indirect cost,
about 88.08% was attributed to permanent disability;
Table 2: Direct and indirect cost of cholera in 2005 international dollars
GROUP 1 GROUP 2 GROUP 3
(A). Direct Cost of 
Diabetes
Sub-Total Cost 
(Int$)
% of grand total Sub-Total Cost 
(Int$)
% of grand total Sub-Total Cost 
(Int$)
% of grand total
(1). Total annual cost of 
insulin
301,619,560 2.71 216,465,240 8.47 3,787,564,806 32.06
(2). Total annual cost of 
syringes
55,045,570 0.49 21,730,768 0.85 379,961,154 3.22
(3). Total annual cost of 
reagent strips
79,265,620 0.71 31,292,306 1.22 547,144,062 4.63
(4). Total annual cost of 
glucose meters
987,900 0.01 390,001 0.02 6,819,144 0.06
(5). Total cost of oral 
drugs
12,818,831 0.12 12,651,474 0.49 243,016,810 2.06
(6). Total cost of OPD 
consultations
155,638,707 1.40 78,781,280 3.08 110,057,519 0.93
(7). Total cost of 
hospitalization
120,850,551 1.09 75,585,203 2.96 128,122,962 1.08
(8). Total cost diabetes 
related test all people
82,442,680 0.74 48,295,109 1.89 1,036,388,236 8.77
(9). Monetary cost borne 
by households
44,551,372 0.40 37,992,583 1.49 486,623,596 4.12
Total Direct Cost 853,220,791 523,183,964 6,725,698,289
(B) Indirect Cost of 
Diabetes
(10). Cost of permanent 
disability
9,055,480,160 81.33 1,791,388,406 70.06 4,482,451,114 37.94
(11). Cost of temporary 
disability
109,022,465 0.98 21,567,225 0.84 53,965,981 0.46
(12). Cost of premature 
deaths among the 
productive
998,019,608 8.96 197,431,911 7.72 494,018,431 4.18
(13). Productivity loss for 
care givers
118,623,416 1.07 23,466,521 0.92 58,718,439 0.50
Grand total indirect 
cost =
10,281,145,649 2,033,854,063 5,089,153,966
GRAND TOTAL COST 
(A+B)
11,134,366,440 100.00 2,557,038,027 100.00 11,814,852,255 100.00BMC International Health and Human Rights 2009, 9:6 http://www.biomedcentral.com/1472-698X/9/6
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1.06% to temporary disability; 9.71% to premature diabe-
tes associated mortality; and 1.15% to productive time
lost by family care givers.
Average costs
Table 3 presents an average cost per case of diabetes for
group 1, 2 and 3 countries. The averages in this table were
obtained by dividing the itemized total costs in Table 2 by
the respective group's number of cases in need of insulin,
syringes, reagent strips, glucose meters, oral drugs, hospi-
tal outpatient department consultations, hospitalization
and diabetes related tests; and numbers of permanently
disabled, temporary disabled, premature deaths and care
givers.
The annual cost of insulin in the three groups of countries
ranged between Int$2,064.5 – $4,582.7 per diabetes case
per year; cost of syringes was Int$270.3 – $459.7 per case;
cost of reagent strips was Int$389.2 – $662.0 per case; cost
of glucose meters was Int$4.9 – $8.3 per case; cost of oral
drugs was Int$15.5 – $51.9 per case; cost of hospital out-
patient consultations was Int$20.0 – $159.8 per case; cost
of hospital admission was Int$155.0-$827.2 per case; cost
diabetes test Int$84.6 – $188.1 per case; health care cost
borne by households was US$45.7 – $88.3 per case; cost
of productive time lost was Int$10,168.9 – $116,215.1
per permanently disabled case; cost of productive time
lost was Int$10.6 – $121.7 per temporarily disabled case;
and cost of productive time lost was Int$10.7 – $121.8 per
caregiver. Cost of productive time lost per premature
death ranged between Int$5,565.0 in group 3 to
$63,599.6 in group 1 of countries.
Table 4 shows the average cost per person with diabetes in
group 1, 2 and 3. These averages were obtained by divid-
ing the itemized total costs in Tables 2 by 974000, 536000
and 5510000 diabetes cases in group 1, 2 and 3 respec-
tively. The annual cost of insulin was Int$309.7 – $687.4
per diabetes patient; cost of syringes was Int$40.5 – $69.0
per diabetes patient; cost of reagent strips was Int$58.4 –
$99.3 per diabetes patient; cost of glucose meters was
Int$0.7 – $1.2 per diabetes patient; cost of oral drugs was
Int$13.2 – $44.1 per diabetes patient; cost of hospital out-
patient consultations was Int$20.0 – $159.8 per diabetes
patient; cost of hospital admission was Int$23.3-$141.0
per diabetes patient; cost diabetes test Int$84.6 – $188.1
per diabetes patient; health care cost borne by households
was Int$45.7 – $88.3 per diabetes patient; cost of produc-
tive time lost was Int$813.5 – $9297.2 per diabetes
patient; cost of productive time lost was Int$9.8 – $111.9
per diabetes patient; and cost of productive time lost was
Int$89.7 – $1024.7 per diabetes patient. Cost of produc-
tive time lost due premature death was Int$2144.3 –
$11431.6 per diabetes patient.
Discussion
The 7.02 million cases of diabetes recorded by countries
of the African Region in 2000 resulted in a total economic
loss of Int$25.51 billion, i.e. $3633 per patient with dia-
betes. Approximately 43.65%, 10.03% and 46.32% of
that loss was incurred by groups 1, 2 and 3 countries,
respectively. Group 1 had only six countries that control a
relatively substantive amount of wealth, which largely
accounts for the high proportion of economic burden of
diabetes. Group 3 consisted of 33 countries with the low-
est GNI per capita; it bore 78% of the total burden of dia-
Table 3: Average cost per case of diabetes and diabetes related death (Int$) in 2005
GROUP 1 GROUP 2 GROUP 3
Cost items Cost per case diabetes per year Cost per diabetes case per year Cost per diabetes case per year
(1). Total annual cost of insulin 2,064.5 2,692.4 4,582.7
(2). Total annual cost of syringes 376.8 270.3 459.7
(3). Total annual cost of reagent strips 542.5 389.2 662.0
(4). Total annual cost of glucose meters 6.8 4.9 8.3
(5). Total cost of oral drugs 15.5 27.8 51.9
(6). Total cost of OPD consultations 159.8 147.0 20.0
(7). Total cost of hospitalization 827.2 940.1 155.0
(8). Total cost diabetes related test all 
people
84.6 90.1 188.1
(9). Monetary cost borne by households 45.7 70.9 88.3
(10). Cost of permanent disability 116,215.1 41,776.8 10,168.9
(11). Cost of temporary disability 121.7 43.7 10.6
(12). Cost of premature deaths among the 
productive
63,599.6 22,862.7 5,565.0
(13). Productivity loss for care givers 121.8 43.8 10.7
GRAND TOTAL COST 11,431.6 4,770.6 2,144.3
Note: The averages in this table were obtained by dividing the itemized total costs in Table 2 by the respective group's number of cases in need of 
insulin, syringes, reagent strips, glucose meters, oral drugs, hospital outpatient department consultations, hospitalization and diabetes related tests; 
and numbers of permanently disabled, temporary disabled, premature deaths and care givers.BMC International Health and Human Rights 2009, 9:6 http://www.biomedcentral.com/1472-698X/9/6
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betes in the Region and the highest economic burden of
diabetes. Comparatively, the total annual costs associated
with diabetes in Latin America and the Caribbean were
estimated at US$65.216 billion [4].
The grand total indirect cost was about Int$8.1 billion
(32%) in the Region, i.e. 1,154.15 per diabetes patient.
The direct cost incurred in treating diabetes was Int$853.2
million in group 1, Int$523.3 million in group 2 and
Int$6.7 billion in group 3. The main driver of direct cost
across the three groups was the total number of people in
need of insulin.
On the other hand, indirect cost of diabetes amounted to
Int$10.3 billion in group 1, Int$2.03 billion in group 2
and Int$5.09 billion in group 3. Permanent disability
accounted for 81.33%, 70.06% and 37.94% of the total
indirect costs in groups 1, 2 and 3 countries, respectively.
Intuitively, this is understandable given the chronic
nature of diabetes disease. This finding is closely similar to
that of Barcelo et al. [4] which found that indirect costs
accounted for 82% of the total costs in the Latin America
and the Caribbean.
The accuracy these estimates hinges on the plausibility of
the assumptions contained in the 'additional file 1: Data
and assumptions used in estimating indirect and direct
costs of diabetes in the WHO African Region'; and their
interpretation should be tempered with the limitations
highlighted below. The reader should keep in mind that
the purpose of total cost of illness studies such as the one
reported in this paper is not to guide policy decisions but
instead to raise awareness among policy-makers and the
public about the negative economic impact of diabetes.
Limitations of the study
a) Disregard of complications in the costing of burden associated with 
diabetes
Various complications such as retinopathy, cardiovascular
diseases, nephropathy and peripheral vascular disease are
associated with diabetes [4]. Most of the deaths associated
with diabetes results from those complications. Unfortu-
nately, due to lack of information on such complications
for the African Region, it was not possible to directly esti-
mate their cost. Thus, it is likely that by disregarding such
complications we will have underestimated the economic
burden.
b) Assumption that those who suffer diabetes disability and mortality 
would have future earnings
In this study we assumed that all those who are temporar-
ily/permanently disabled by diabetes or die from causes
associated with diabetes would have future earnings. This
assumption can be contested especially in African coun-
tries where the formal sectors are small and hence the pro-
portion of people in formal employment is small. In
situations where unemployment rate is high, the marginal
productivity of labor might be less than the average.
Should this be the case, the use of gross national income
per capita might over-estimate the economic burden of
diabetes.
Table 4: Average cost per person with diabetes (Int$) in 2005
GROUP 1 GROUP 2 GROUP 3
Summary of direct Cost of Diabetes Cost per diabetes patient (Int$) Cost per diabetes patient (Int$) Cost per diabetes patient (Int$)
(1). Total annual cost of insulin 309.7 403.9 687.4
(2). Total annual cost of syringes 56.5 40.5 69.0
(3). Total annual cost of reagent strips 81.4 58.4 99.3
(4). Total annual cost of glucose meters 1.0 0.7 1.2
(5). Total cost of oral drugs 13.2 23.6 44.1
(6). Total cost of OPD consultations 159.8 147.0 20.0
(7). Total cost of hospitalization 124.1 141.0 23.3
(8). Total cost diabetes related test all 
people
84.6 90.1 188.1
(9). Monetary cost borne by households 45.7 70.9 88.3
Total Direct Cost 876.0 976.1 1,220.6
Summary of Indirect Cost of Diabetes
(10). Cost of permanent disability 9,297.2 3,342.1 813.5
(11). Cost of temporary disability 111.9 40.2 9.8
(12). Cost of premature deaths among the 
productive
1,024.7 368.3 89.7
(13). Productivity loss for care givers 121.8 43.8 10.7
Grand total indirect cost = 10,555.6 3,794.5 923.6
GRAND TOTAL COST 11,431.6 4,770.6 2,144.3
Note: These averages were obtained by dividing the itemized total costs in Tables 2 by 974000, 536000 and 5510000 diabetes cases in group 1, 2 
and 3 respectively.BMC International Health and Human Rights 2009, 9:6 http://www.biomedcentral.com/1472-698X/9/6
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c) Use of human capital approach
It is an approach that values health benefits in terms of the
present value of future lost output (as proxied normally
by earnings and other labour costs). This approach values
health benefits in terms of production gained due to a
decrease in mortality (loss of productive years), morbidity
(loss of working time), and debility (loss of productive
capacity at work). The use of human capital approach
assumes that the objective function that society is trying to
maximize through improved health is Gross National
Income; and wages in the African Region are a precise
indicator of productivity. The approach has been criti-
cized for not being consistent with the basic rationale of
the economic calculus used in cost-benefit-analysis, i.e.
the potential Pareto optimality; and the fact that people
value prevention of premature death, morbidity and
debility per se rather than their concern to preserve pro-
ductive resources and maintain future levels of GNP,
among others [21].
d) Assumption that all diabetes cases receive diagnostic tests
We have assumed that all diabetes cases receive five diag-
nostic tests. In reality, not all diabetes patients in the Afri-
can Region would be able to undergo all the tests. Thus,
by assuming that all patients would receive the five tests
we may have overestimated the actual cost of diagnosis in
the Region.
e) Omission of intangible costs
Apart from the physical pain associated with diabetes
complications, it has other psychological costs. For exam-
ple, many communities in Africa may be averse to getting
married in families with history of diabetes, and this may
have enormous psychological costs on the families con-
cerned. Unfortunately, since majority of the data used in
this study were obtained from secondary sources, it was
not possible to conduct a household survey that would
have made it possible to estimate the intangible costs
using contingent willingness-to-pay approach [17,22].
f) Use of per capita GNI to value-productive time lost
This study attempted to estimate the loss in the gross
national income (GNI) and not the total economic cost of
disability and premature mortality associated diabetes.
The social value of the contribution that women make to
African societies is greater than that captured in GNI cal-
culations. This is because the International Labour Organ-
ization's (ILO) definition of labour force includes the
employed (including the armed forces), the unemployed,
and the first-time job-seekers, but excludes full-time
homemakers and other unpaid caregivers and workers in
the informal sector. The majority of the women in Africa
are either full-time homemakers and/or informal sector
workers, and, thus, their invaluable contribution to soci-
ety is excluded from GNI calculations [23].
Conclusion
In spite of data limitations, the estimates reported here
show that diabetes imposes a substantive economic bur-
den on countries of the African Region. That heavy burden
underscores the urgent need for increased investments to
fully implement the WHO Regional Committee for Africa
[24], World Health Assembly [25,26] and United Nations
General Assembly [27] resolutions on the prevention and
control of diabetes.
In addition, given the high degree of ignorance about the
magnitude of the epidemiological and economic burdens
of diabetes in the WHO African Region, there is an urgent
need for further research to determine:
￿ national-level epidemiological burden of diabetes,
measured in terms of its prevalence, incidence, mortal-
ity, and, probably, disability-adjusted life years lost;
￿ national-level economic burden of diabetes, broken
down by different productive and social sectors and
occupations of patients and relatives; and
￿ national-level costs and effectiveness of alternative
preventive, diagnostic and treatment interventions of
diabetes to aid choice of cost-effective strategies.
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